Protocol Ledger

NCT04549168 · Phase III · COMPLETED

A Study of Lemborexant in Chinese Participants With Insomnia Disorder

Interventional Phase III clinical trial protocol NCT04549168 sponsored by Eisai in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-11-06 Enrollment: 194 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04549168
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)194 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04549168
Protocol FieldVerified Registry Value
NCT IdentifierNCT04549168
Consolidated Lead SponsorEisai
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment194 participants (ACTUAL)
Registered Start Date2020-11-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI